ReviewOrphanet journal of rare diseases2025
Inherited metabolic disorders: presentation, clinical types, laboratory diagnosis and genetic markers.
Review in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The invisible emergencies: metabolic and neuro-critical disorders often missed in the pediatric ED - a narrative review.International journal of emergency medicine · 2026Review
- Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders.Frontiers in genome editing · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inherited metabolic disorders (IMDs) are classified under rare genetic diseases almost always presenting in newborn and infants. IMDs are classified according to the clinical presentation, diagnosis and prognosis. Several factors are involved in the IMDs pathogenesis. Moreover, almost all IMDs follows the autosomal recessive inheritance pattern. At the basis of these diseases lie genetic mutations that affect metabolic pathways. The diagnosis is made by clinical manifestations in addition to biochemical tests and genetic analysis. Due to the different metabolic pathways involved, the multi-omics approaches can significantly increase diagnosis sensitivity. Early identification and diagnosis of IMD are critical to avoid death or neurological defects. In developing countries, lack of timely diagnosis exists mostly due to socioeconomic factors and unawareness. Research needs to be conducted to find better options for the treatment of IMDs. Understanding the molecular mechanisms of IMDs would be helpful in understanding the challenges that exist for the treatment of IMDs. This review aims to provide understanding regarding the pathogenesis of IMDs. Also, to highlight the challenges that exist in the effective treatment and diagnosis of IMDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.